drugset / Trial / NCT05852769

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

NCT05852769

Phase 1 Completed 18 enrolled Bristol-Myers Squibb
NaSequentialOpen-labelTreatment

Summary

This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.

Timeline

Start
2023-05-31
Primary completion
2023-08-24
Completion
2023-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986196 Unknown
Subject Caffeine Small molecule
Subject Digoxin Other / unclassified
Subject Flurbiprofen Small molecule
Subject Midazolam Small molecule
Subject Montelukast Other / unclassified
Subject Omeprazole Other / unclassified
Subject Pravastatin Small molecule

Indications

No indication recorded.